Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression = 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).Masini,S., Antoñanzas Basa,M., Calles,A., Cabellos,R.A., De Elejoste Echebarria,I., Traseira Puchol,C., Martinez Kareaga,M., Cabezon-Gutierrez,L., Escoin Perez,M.C., Lage,Y., Garcia Lorenzo,E., Navarro,F., Sereno,M., Falagán Martínez,S., García-Benito,C., Masfarre Pinto,L., Avila Andrade,C., Sequero,S., Mosquera Martinez,J., López-Martín,A., Azkárate Martínez,A., Martín-Soberón,M.C., Lucia-Gozalvez,C., Rubio,J., Tallafigo,L., Garrido,A., Peressini,M., Torres-Jimenez,J., Zurera,M., Bote,H., Ponce,S., Paz-Ares,L., Zugazagoitia,J., Baena,J.. Cancers, 17, 0-0. 2025 Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.Les, I, de Haedo, D, Martinez, M, Ibáñez-Beroiz, B, Moreno, A, de Elejoste, I, Campillo-Calatayud, A, Perez-Francisco, I, Cabero, M, Elejalde, I, Arrazubi, V. Frontiers in Immunology, 16, 0-0. 2025 Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer.Nadal, E., Moran, T., Estival, A., Sala, M. A., Antonanzas, M., Gonzalez, J. G., Diz-Tain, M. P., Martinez, M., Azcona, E., Baena, J., Campos, B., Cumplido, J. D., Cerezo, S., Diaz-Serrano, A., Guirado, M., Mielgo, X., Saigi, M., Vidales, Z.. Esmo Real World Data And Digital Oncology, 8, 0-0. 2025 KRAS Mutation Status in Non-Small Cell Lung Cancer: Distribution Across Occupational Categories..Serna-Blasco, Roberto, Medina, Karla, Sala, Maria Angeles, Aguiar, David, Diaz-Serrano, Asuncion, Antonanzas, Monica, Gonzalez Larriba, Jose Luis, Ocana, Julio, Mielgo, Xabier, Fernandez, Inmaculada, Lopez-Castro, Rafael, Cobo, Manuel, Martinez, Mireia, Villa, Jose Carlos, Rosado, Petra, Lopez, Ana, Guirado, Maria, Viteri, Santiago, Rodriguez, Delvys, Garcia, Florencia, Simon, Soraya, Moreno, Maria Angeles, Catot, Silvia, Mediavilla, Pilar, Simon, Natalia Garcia, Octavio, Leonor, Calvo, Virginia, Romero, Atocha, Provencio, Mariano. Chest, 0-0. 2025 Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study..Serna-Blasco, Roberto, Mediavilla-Medel, Pilar, Medina, Karla, Sala, Maria Angeles, Aguiar, David, Diaz-Serrano, Asuncion, Antonanzas, Monica, Ocana, Julio, Mielgo, Xabier, Fernandez, Inmaculada, Lopez-Castro, Rafael, Cobo, Manuel, Martinez, Mireia, Villa, Jose Carlos, Rosado, Petra, Lopez, Ana, Guirado, Maria, Viteri, Santiago, Rodriguez, Delvys, Garcia, Florencia, Simon, Soraya, Moreno, Maria Angeles, Catot, Silvia, Gonzalez Larriba, Jose Luis, Salas, Clara, Calvo, Virginia, Romero, Atocha, Provencio, Mariano. LUNG CANCER, 204, 108550-108550. 2025 1058P Transcriptomic insights into cisplatin resistance in testicular germ cell tumors: Molecular pathways and tumor microenvironment.MARTINEZ KAREAGA, MIREIA. Annals of Oncology, 0-0. 2025 1533P Immune-related adverse events and pre-existing autoimmune disease as prognostic biomarkers in patients treated with ICIs: Results from the AUTENTIC study (NCT05280055).MARTINEZ KAREAGA, MIREIA. Annals of Oncology, 0-0. 2025 1560P Role of interleukin-6 in immune-related adverse events occurrence: Analysis of a real-world, multicenter, prospective pan-cancer cohort.MARTINEZ KAREAGA, MIREIA. Annals of Oncology, 0-0. 2025 2371eP HUMA-LUNG project: Scalable implementation of a thoracic tumour functional unit (TTFU) to advance value-based care in a tertiary hospital.MARTINEZ KAREAGA, MIREIA. Annals of Oncology, 0-0. 2025 45P: Extended follow-up confirmed real-world efficacy and safety of cemiplimab monotherapy in advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression.MARTINEZ KAREAGA, MIREIA.
Journal of Thoracic Oncology, 0-0. 2025
